# Ascletis Announces Inclusion in the Hong Kong Stock Connect List under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect Programs

- Link: https://www.thailand-business-news.com/pr-news/ascletis-announces-inclusion-in-the-hong-kong-stock-connect-list-under-the-shanghai-hong-kong-stock-connect-and-the-shenzhen-hong-kong-stock-connect-programs
- Published: 2026-09-07T11:15:00+07:00
- Author: PR Newswire

|   |

HONG KONG, Sept. 7, 2026 /PRNewswire/ — Ascletis Pharma Inc. (HKEX: 1672, "Ascletis")
announces that, the ordinary shares of the Company (the "Shares"), which trade on
The Stock Exchange of Hong Kong Limited (the "HK Stock Exchange"), have been included
in the list of eligible securities under the Shanghai-Hong Kong Stock Connect and
Shenzhen-Hong Kong Stock Connect (collectively, the "Hong Kong Stock Connect") programs,
both with effect from September 7, 2026, pursuant to the announcements issued by
the Shanghai Stock Exchange and the Shenzhen Stock Exchange, recently. Following
the inclusion of the Shares, eligible investors in Chinese Mainland will be able
to trade the Shares through the Hong Kong Stock Connect channel.

The Company believes the inclusion of the Shares in the trading mechanism of the
Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect demonstrates
market recognition of the Company’s investment value and growth prospects. The Company
expects the inclusion of the Shares as eligible securities will help further expand
the shareholder base of the Company, increase the trading liquidity of the Shares,
and support the innovation-driven and sustainable growth of the Company in the long
term.

**About the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect**

The Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect are
mutual stock market access mechanisms between Chinese Mainland and the Hong Kong
Special Administrative Region, under which the Shanghai Stock Exchange and the Shenzhen
Stock Exchange have established technical connectivity with the HK Stock Exchange,
respectively, to enable investors in Chinese Mainland and the Hong Kong Special 
Administrative Region to trade eligible securities listed on each other’s market
through their local securities companies or brokers.

**About Ascletis Pharma Inc.**

Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the 
development and commercialization of potentially best-in-class and first-in-class
therapeutics to treat metabolic diseases. Utilizing its proprietary Artificial Intelligence-
assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (
ULAP) technologies as well as Peptide Oral Transport ENhancement Technology (POTENT),
Ascletis has developed multiple drug candidates in-house, including both small molecules
and peptides, such as its lead program, ASC30, a once-daily oral small molecule 
GLP-1R agonist for chronic weight management and diabetes; ASC30_48FDC, a once-daily
oral small molecule dual agonist, a fixed dose combination of ASC30 (GLP-1R agonist)
and ASC48 (GIPR agonist), ASC30_48_39FDC, a once-daily oral small molecule triple
agonist, a fixed dose combination of ASC30 (GLP-1R agonist), ASC48 (GIPR agonist)
and ASC39 (amylin receptor agonist (SARA)), ASC39, an eloralintide-like potent selective
amylin receptor agonist (SARA) once-daily oral small molecule, ASC30_39FDC, a once-
daily oral small molecule dual agonist, a fixed dose combination of ASC30 (GLP-1R
agonist) and ASC39 (amylin receptor agonist (SARA)), ASC36, an amylin peptide, designed
to be administered once monthly to once quarterly subcutaneously and once daily 
orally, ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide
agonist, ASC36_35FDC, a once-monthly subcutaneous triple peptide agonist, a fixed
combination of ASC36 (amylin receptor agonist) and ASC35 (GLP-1R/GIPR agonist), 
ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist, designed to be administered once
monthly subcutaneously and once daily orally, and ASC36_37FDC, a once-monthly subcutaneous
quadruple peptide agonist, a fixed dose combination of ASC36 (amylin receptor agonist)
and ASC37 (GLP-1R/GIPR/GCGR agonist), for chronic weight management. Ascletis is
listed on the Hong Kong Stock Exchange (1672.HK).

For more information, please visit [www.ascletis.com](https://www.ascletis.com/).

Contact：

Peter Vozzo
ICR Healthcare443-231-0505 (U.S.)[Peter.vozzo@icrhealthcare.com](https://www.thailand-business-news.com/pr-news/Peter.vozzo@icrhealthcare.com)

Ascletis Pharma Inc. PR and IR Teams
+86-181-0650-9129 (China)[pr@ascletis.com](https://www.thailand-business-news.com/pr-news/pr@ascletis.com)
[ir@ascletis.com](https://www.thailand-business-news.com/pr-news/ir@ascletis.com)

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Ascletis Announces Inclusion in the Hong Kong Stock Connect List under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect Programs ](http://www.prnasia.com/story/archive/5041544_AE41544_0?rand=184833)